The Korean journal of internal medicine

  • 제33권2호
  • /
  • Pages.397-406
  • /
  • 2018
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Atorvastatin inhibits osteoclast differentiation by suppressing NF-κB and MAPK signaling during IL-1β-induced osteoclastogenesis

  • Lee, Won-Seok (Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital) ;
  • Lee, Eun-Gyeong (Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital) ;
  • Sung, Myung-Soon (Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital) ;
  • Choi, Yun-Jung (Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital) ;
  • Yoo, Wan-Hee (Division of Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School, Research Institute of Clinical Medicine of Chonbuk National University- Biomedical Research Institute of Chonbuk National University Hospital)
  • 투고 : 2015.07.28
  • 심사 : 2016.03.11
  • 발행 : 2018.03.01
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: To define the effect of statins on interleukin $1{\beta}$ (IL-$1{\beta}$)-induced osteoclastogenesis and elucidate the underlying mechanisms. Methods: Bone marrow cells were obtained from 5-week-old male ICR (Institute for Cancer Research) mice, and they were cultured to differentiate them into osteoclasts with macrophage colony-stimulating factor and the receptor activator of nuclear factor (NF)-${\kappa}B$ ligand in the presence or absence of IL-$1{\beta}$ or atorvastatin. The formation of osteoclasts was evaluated by tartrate-resistant acid phosphatase (TRAP) staining and resorption pit assay with dentine slice. The molecular mechanisms of the effects of atorvastatin on osteoclastogenesis were investigated using reverse transcription polymerase chain reaction and immunoblotting for osteoclast specific molecules. Results: Atorvastatin significantly reduced the number of TRAP-positive multinucleated cells as well as the bone resorption area. Atorvastatin also downregulated the expression of the NF of activated T-cell c1 messenger RNA and inhibited the expression of osteoclast-specific genes. A possible underlying mechanism may be that atorvastatin suppresses the degradation of the inhibitors of NF-${\kappa}B$ and blocks the activation of the c-Jun N-terminal kinase, extracellular signal-regulated kinase, and p38; thus, implicating the NF-${\kappa}B$ and mitogen-activated protein kinases pathway in this process. Conclusions: Atorvastatin is a strong inhibitor of inflammation-induced osteoclastogenesis in inflammatory joint diseases.

키워드

과제정보

연구 과제 주관 기관 : Biomedical Research Institute, Chonbuk National University Hospital

참고문헌

  1. Schett G, Gravallese E. Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 2012;8:656-664. https://doi.org/10.1038/nrrheum.2012.153
  2. Gravallese EM, Goldring SR. Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000;43:2143-2151. https://doi.org/10.1002/1529-0131(200010)43:10<2143::AID-ANR1>3.0.CO;2-S
  3. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357. https://doi.org/10.1210/edrv.20.3.0367
  4. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Boyle WJ, Riggs BL. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 2000;15:2-12. https://doi.org/10.1359/jbmr.2000.15.1.2
  5. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis- inhibitory factor and is identical to TRANCE/ RANKL. Proc Natl Acad Sci U S A 1998;95:3597-3602. https://doi.org/10.1073/pnas.95.7.3597
  6. Kong YY, Yoshida H, Sarosi I, et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 1999;397:315-323. https://doi.org/10.1038/16852
  7. Lee ZH, Kim HH. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003;305:211-214. https://doi.org/10.1016/S0006-291X(03)00695-8
  8. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003;4:638-649. https://doi.org/10.1038/nrg1122
  9. Matsuo K, Galson DL, Zhao C, et al. Nuclear factor of activated T-cells (NFAT) rescues osteoclastogenesis in precursors lacking c-Fos. J Biol Chem 2004;279:26475-26480. https://doi.org/10.1074/jbc.M313973200
  10. Takayanagi H, Kim S, Koga T, et al. Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 2002;3:889-901. https://doi.org/10.1016/S1534-5807(02)00369-6
  11. Stern RH, Yang BB, Hounslow NJ, MacMahon M, Abel RB, Olson SC. Pharmacodynamics and pharmacokinetic- pharmacodynamic relationships of atorvastatin, an HMG-CoA reductase inhibitor. J Clin Pharmacol 2000;40:616-623. https://doi.org/10.1002/j.1552-4604.2000.tb05987.x
  12. Malhotra HS, Goa KL. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia. Drugs 2001;61:1835-1881. https://doi.org/10.2165/00003495-200161120-00012
  13. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997;100:2671-2679. https://doi.org/10.1172/JCI119812
  14. Blaschke S, Viereck V, Schwarz G, Klinger HM, Guerluek S, Muller GA. Anti-inflammatory effects of atorvastatin on peripheral blood mononuclear cells and synovial fibroblasts in rheumatoid arthritis. Scand J Rheumatol 2009;38:235-239. https://doi.org/10.1080/03009740802572475
  15. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001;7:687-692. https://doi.org/10.1038/89058
  16. Majima T, Komatsu Y, Fukao A, Ninomiya K, Matsumura T, Nakao K. Short-term effects of atorvastatin on bone turnover in male patients with hypercholesterolemia. Endocr J 2007;54:145-151. https://doi.org/10.1507/endocrj.K06-127
  17. Nakagawa T, Takahashi M, Ozaki T, et al. Autoinhibitory regulation of p73 by delta Np73 to modulate cell survival and death through a p73-specific target element within the delta Np73 promoter. Mol Cell Biol 2002;22:2575-2585. https://doi.org/10.1128/MCB.22.8.2575-2585.2002
  18. Mbalaviele G, Chen H, Boyce BF, Mundy GR, Yoneda T. The role of cadherin in the generation of multinucleated osteoclasts from mononuclear precursors in murine marrow. J Clin Invest 1995;95:2757-2765. https://doi.org/10.1172/JCI117979
  19. Yagi M, Miyamoto T, Sawatani Y, et al. DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells. J Exp Med 2005;202:345-351. https://doi.org/10.1084/jem.20050645
  20. Verrier S, Hogan A, McKie N, Horton M. ADAM gene expression and regulation during human osteoclast formation. Bone 2004;35:34-46. https://doi.org/10.1016/j.bone.2003.12.029
  21. Garrett IR, Gutierrez G, Mundy GR. Statins and bone formation. Curr Pharm Des 2001;7:715-736. https://doi.org/10.2174/1381612013397762
  22. Mundy G, Garrett R, Harris S, et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949. https://doi.org/10.1126/science.286.5446.1946
  23. Maritz FJ, Conradie MM, Hulley PA, Gopal R, Hough S. Effect of statins on bone mineral density and bone histomorphometry in rodents. Arterioscler Thromb Vasc Biol 2001;21:1636-1641. https://doi.org/10.1161/hq1001.097781
  24. Abud-Mendoza C, de la Fuente H, Cuevas-Orta E, Baranda L, Cruz-Rizo J, Gonzalez-Amaro R. Therapy with statins in patients with refractory rheumatic diseases: a preliminary study. Lupus 2003;12:607-611. https://doi.org/10.1191/0961203303lu429oa
  25. El-Barbary AM, Hussein MS, Rageh EM, Hamouda HE, Wagih AA, Ismail RG. Effect of atorvastatin on inflammation and modification of vascular risk factors in rheumatoid arthritis. J Rheumatol 2011;38:229-235. https://doi.org/10.3899/jrheum.100582
  26. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double- blind, randomised placebo-controlled trial. Lancet 2004;363:2015-2021. https://doi.org/10.1016/S0140-6736(04)16449-0
  27. Kim JY, Lee EY, Lee EB, et al. Atorvastatin inhibits osteoclastogenesis by decreasing the expression of RANKL in the synoviocytes of rheumatoid arthritis. Arthritis Res Ther 2012;14:R187. https://doi.org/10.1186/ar4018
  28. Machold KP, Stamm TA, Nell VP, et al. Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease. Rheumatology (Oxford) 2007;46:342-349.
  29. Gitter BD, Labus JM, Lees SL, Scheetz ME. Characteristics of human synovial fibroblast activation by IL-1 beta and TNF alpha. Immunology 1989;66:196-200.
  30. Jules J, Zhang P, Ashley JW, et al. Molecular basis of requirement of receptor activator of nuclear factor ${\kappa}B$ signaling for interleukin 1-mediated osteoclastogenesis. J Biol Chem 2012;287:15728-15738. https://doi.org/10.1074/jbc.M111.296228
  31. Asagiri M, Sato K, Usami T, et al. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 2005;202:1261-1269. https://doi.org/10.1084/jem.20051150
  32. Partington GA, Fuller K, Chambers TJ, Pondel M. Mitf- PU.1 interactions with the tartrate-resistant acid phosphatase gene promoter during osteoclast differentiation. Bone 2004;34:237-245. https://doi.org/10.1016/j.bone.2003.11.010
  33. Soysa NS, Alles N, Aoki K, Ohya K. Osteoclast formation and differentiation: an overview. J Med Dent Sci 2012;59:65-74.
  34. Lomaga MA, Yeh WC, Sarosi I, et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 1999;13:1015-1024. https://doi.org/10.1101/gad.13.8.1015
  35. Naito A, Azuma S, Tanaka S, et al. Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 1999;4:353-362. https://doi.org/10.1046/j.1365-2443.1999.00265.x
  36. Xing L, Xiu Y, Boyce BF. Osteoclast fusion and regulation by RANKL-dependent and independent factors. World J Orthop 2012;3:212-222. https://doi.org/10.5312/wjo.v3.i12.212
  37. Yang M, Birnbaum MJ, MacKay CA, Mason-Savas A, Thompson B, Odgren PR. Osteoclast stimulatory transmembrane protein (OC-STAMP), a novel protein induced by RANKL that promotes osteoclast differentiation. J Cell Physiol 2008;215:497-505. https://doi.org/10.1002/jcp.21331
  38. Iwai K, Ishii M, Ohshima S, Miyatake K, Saeki Y. Abundant expression of tetraspanin CD9 in activated osteoclasts in ovariectomy-induced osteoporosis and in bone erosions of collagen-induced arthritis. Rheumatol Int 2008;28:225-231. https://doi.org/10.1007/s00296-007-0424-4
  39. Lee SH, Rho J, Jeong D, et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 2006;12:1403-1409. https://doi.org/10.1038/nm1514

피인용 문헌

  1. Tanshinone I Mitigates Steroid-Induced Osteonecrosis of the Femoral Head and Activates the Nrf2 Signaling Pathway in Rats vol.2021, pp.None, 2018, https://doi.org/10.1155/2021/8002161
  2. Tocotrienol regulates osteoclastogenesis in rheumatoid arthritis vol.36, pp.suppl1, 2018, https://doi.org/10.3904/kjim.2019.372
  3. IL1RN promotes osteoblastic differentiation via interacting with ITGB3 in osteoporosis vol.53, pp.3, 2021, https://doi.org/10.1093/abbs/gmaa174